Sign in

Private company

LumiraDx Ltd

LumiraDx Ltd is a pharmaceutical preparations company in the Cayman Islands.1 It is headquartered in London, United Kingdom.1

Last updated Oct 21, 2026.

Overview

$254.5MRevenue, fiscal 20222
-$447.6MNet income, fiscal 20222
  • IndustryPharmaceutical Preparations1
  • HeadquartersLondon, United Kingdom1
  • Incorporated inCayman Islands3
  • Business address3 More London Riverside, London, X0 Se1 2Aq3
  • Filer categoryAccelerated filer, Emerging growth company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-13.9%Gross margin2
-126.3%Operating margin2
-175.9%Net margin2
-39.6%Revenue growth, 20222
-$187.1MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue40¢$289.8M
  • Research and development20¢$141.6M
  • Selling, general and admin20¢$144.5M
  • Interest19¢$136.5M
  • Income tax1¢$4.3M

Out of $254.5M in revenue.2 The company lost money this year.

Financial statements

Revenue42$254.5M in 2022+1000% since 2019
0$200.0M$400.0M$600.0M2019: $23.1M$23.1M20192020: $139.2M$139.2M2020+501%2021: $421.4M$421.4M2021+203%2022: $254.5M$254.5M2022−40%
Gross profit42-$35.3M in 2022
-$50.0M0$50.0M$100.0M$150.0M$200.0M2019: $8.8M$8.8M20192020: $52.9M$52.9M2020+500%2021: $151.5M$151.5M2021+186%2022: -$35.3M-$35.3M2022
Operating income42-$321.4M in 2022+179% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M02019: -$115.0M-$115.0M20192020: -$100.7M-$100.7M2020−12%2021: -$145.4M-$145.4M2021+44%2022: -$321.4M-$321.4M2022+121%
Net income42-$447.6M in 2022+236% since 2019
-$600.0M-$400.0M-$200.0M02019: -$133.1M-$133.1M20192020: -$241.0M-$241.0M2020+81%2021: -$100.8M-$100.8M2021−58%2022: -$447.6M-$447.6M2022+344%
Fiscal year20182019202020212022
Revenue$23.1M4$139.2M2$421.4M2$254.5M2
Cost of revenue$269.9M2$289.8M2
Gross profit$8.8M4$52.9M2$151.5M2-$35.3M2
Research and development$130.2M2$141.6M2
Selling, general and admin$37.3M4$46.1M2$130.5M2$144.5M2
Operating income-$115.0M4-$100.7M2-$145.4M2-$321.4M2
Interest$117.9M2$136.5M2
Income before tax-$97.9M2-$443.3M2
Income tax$2.8M2$4.3M2
Net income-$133.1M4-$241.0M2-$100.8M2-$447.6M2
Earnings per share-$1.014-$1.822-$0.622-$1.592
Earnings per share (diluted)-$1.014-$1.822-$0.622-$1.592
Shares (weighted, basic)163.3M shares2282.2M shares2
Shares (weighted, diluted)163.3M shares2282.2M shares2

Compare LumiraDx Ltd with another company

Corporate structure

LumiraDx Ltd sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of LumiraDx Ltd

  • Senvest Management, LLC Filed SC 13G/A on LumiraDx Ltd, latest Nov 12, 2024 (4 filings since Feb 9, 2022)
  • PETRICHOR HEALTHCARE CAPITAL MANAGEMENT LP Filed SC 13G/A on LumiraDx Ltd, latest Feb 12, 2024 (3 filings since Feb 24, 2022)
  • Willard L. Umphrey Filed SC 13D/A on LumiraDx Ltd, latest Dec 29, 2023 (4 filings since Sep 7, 2022)
  • David Scott Filed SC 13D/A on LumiraDx Ltd, latest Nov 8, 2023 (2 filings since Sep 6, 2022)
  • Jerome F. McAleer Filed SC 13D/A on LumiraDx Ltd, latest Nov 8, 2023 (2 filings since Aug 24, 2022)
  • Zwanziger Ventures LLC Filed SC 13D/A on LumiraDx Ltd, latest Nov 7, 2023 (3 filings since Feb 24, 2022)
  • Morningside Venture Investments Ltd Filed SC 13D/A on LumiraDx Ltd, latest Feb 23, 2023 (3 filings since Feb 14, 2022)
  • Gates Foundation Filed SC 13D on LumiraDx Ltd, latest Aug 3, 2022 (2 filings since Jul 15, 2022)
  • LumiraDx Ltd London, United Kingdom

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What LumiraDx Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$113.4M2 Dec 31, 2022$173.4M2 Dec 31, 2021−34.6%
Operating-lease assets (leased space)$16.6M2 Dec 31, 2022$27.7M2 Dec 31, 2021−40.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$100.0M2 Dec 31, 2022$132.1M2 Dec 31, 2021−24.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$21.4M4 Dec 31, 2021$24.7M4 Dec 31, 2020−13.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$90.0M2 Dec 31, 2022$149.1M2 Dec 31, 2021−39.6%

Filings

102 filings to the SEC since October 2021: 2 annual reports, 23 large holders, 77 other. The latest 20:

  1. Nov 12, 2024SC 13G/A LUMIRADX LIMITED EDGAR
  2. Oct 4, 20246-K EDGAR
  3. Feb 12, 2024SC 13G/A EDGAR
  4. Feb 9, 2024SC 13G/A LUMIRADX LIMITED EDGAR
  5. Feb 6, 20246-K EDGAR
  6. Dec 29, 2023SC 13D/A AMENDMENT TO FORM SC 13D EDGAR
  7. Dec 29, 20236-K EDGAR
  8. Dec 26, 2023SC 13D/A AMENDMENT TO FORM SC 13D EDGAR
  9. Dec 20, 2023SC 13D/A EDGAR
  10. Dec 11, 20236-K EDGAR
  11. Nov 21, 20236-K EDGAR
  12. Nov 8, 2023SC 13D/A EDGAR
  13. Nov 8, 2023SC 13D/A EDGAR
  14. Nov 7, 2023SC 13D/A EDGAR
  15. Nov 7, 20236-K EDGAR
  16. Nov 6, 20236-K EDGAR
  17. Nov 1, 20236-K EDGAR
  18. Oct 31, 20236-K EDGAR
  19. Oct 27, 20236-K EDGAR
  20. Oct 23, 20236-K EDGAR

The 102 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How LumiraDx Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLumiraDx Ltd1
  • CIK0001685428
  • Filer statusAccelerated filer<br>emerging growth company1
  • Incorporated inCayman Islands1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address3 More London Riverside, London, X0 SE1 2AQ1
  • Phone011 44 1786 4304111
  • Shares outstanding154,224,500 as of Dec 31, 20222
  • On EDGAR sinceOct 13, 20161
  • Filings147 in all: 6-K (52), CORRESP (9), D (9), SC 13D/A (8), UPLOAD (7), 424B3 (6), SC 13D (6), EFFECT (5)1
    All 30 form types

    SC 13G/A (5), DRS/A (4), SC 13G (4), 20-F (3), DRS (3), F-1 (3), F-4/A (3), S-8 (3), 425 (2), D/A (2), SEC STAFF LETTER (2), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), DRSLTR (1), F-1/A (1), F-3 (1), F-4 (1), POS AM (1), POS EX (1), RW (1)

  • Latest filingsAnnual report (20-F) May 1, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12